LOGIN  |  REGISTER
C4 Therapeutics
Astria Therapeutics

Labcorp's Planned Spin-off, Fortrea, to Host 2023 Investor Day

June 05, 2023 | Last Trade: US$278.46 0.57 0.21

BURLINGTON, N.C., June 5, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced Fortrea, the new company to be formed by the planned spin-off of Labcorp's Clinical Development and Commercialization Services business, will host its inaugural Investor Day on Tuesday, June 6, 2023, in New York City at 9 a.m. ET.

This event will review Fortrea's business, operational outlook, growth strategies, and financial highlights with presentations from management including Chairman & CEO Tom Pike and CFO Jill McConnell. The presentations will be followed by a Q&A session.

A live webcast of the event will be available through the Labcorp Investor Relations website. For additional information on the event, please contact Hima Inguva, Fortrea's Head of Investor Relations, at This email address is being protected from spambots. You need JavaScript enabled to view it..

Transaction Update

Following the completion of the spin-off, Fortrea's common stock will be listed on The Nasdaq Stock Market LLC under the ticker symbol "FTRE." Labcorp common shares will continue to trade on the New York Stock Exchange under the symbol "LH."

The planned spin-off remains on track to be completed in mid-2023, subject to the satisfaction of certain customary conditions, including, among others, the receipt of final approval by the Company's board of directors, the receipt of appropriate assurances regarding the tax-free nature of the separation, and the effectiveness of any required filings with the Securities and Exchange Commission. Until the spin-off is complete, Fortrea's products, services and offerings are still owned and operated by Labcorp. Learn more about Fortrea at Fortrea.com.

About Labcorp

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With more than 80,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14.9 billion in FY2022. Learn more about us at Labcorp.com or follow us on LinkedIn and Twitter @Labcorp

 

Viking Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page